[Value-based cancer care. From traditional evidence-based decision making to balanced decision making within frameworks of shared values]

Recenti Prog Med. 2016 Apr;107(4):175-80. doi: 10.1701/2218.23926.
[Article in Italian]

Abstract

Clinical decision making in oncology is based so far on the evidence of efficacy from high-quality clinical research. Data collection and analysis from experimental studies provide valuable insight into response rates and progression-free or overall survival. Data processing generates valuable information for medical professionals involved in cancer patient care, enabling them to make objective and unbiased choices. The increased attention of many scientific associations toward a more rational resource consumption in clinical decision making is mirrored in the Choosing Wisely campaign against the overuse or misuse of exams and procedures of little or no benefit for the patient. This cultural movement has been actively promoting care solutions based on the concept of "value". As a result, the value-based decision-making process for cancer care should not be dissociated from economic sustainability and from ethics of the affordability, also given the growing average cost of the most recent cancer drugs. In support of this orientation, the National Comprehensive Cancer Network (NCCN) has developed innovative and "complex" guidelines based on values, defined as "evidence blocks", with the aim of assisting the medical community in making overall sustainable choices.

MeSH terms

  • Antineoplastic Agents
  • Decision Making*
  • Humans
  • Neoplasms

Substances

  • Antineoplastic Agents